17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

You may be eligible if

• Histologically or cytologically confirmed diagnosis of 1 of the following hematologic malignancies:
• * Acute myeloid leukemia or acute lymphoblastic leukemia
• * Not a candidate for potentially curative therapy
• * WBC ≤ 10,000/mm\^3 OR WBC ≤ 40,000/mm\^3 that is stable for 5 days (hydroxyurea allowed)
• * No acute promyelocytic leukemia
• * Non-Hodgkin's lymphoma (NHL), including 1 of the following subtypes:
• * Small lymphocytic lymphoma
• * Marginal zone lymphoma
• * Lymphoplasmacytic lymphoma
• * Follicular lymphoma
• * Mantle cell lymphoma
• * Diffuse large B-cell lymphoma
• * Anaplastic large cell lymphoma
• * Peripheral T-cell lymphoma
• * Extranodal NK/T cell lymphoma (nasal and nasal type)
• * Enteropathy-type T-cell lymphoma
• * Hepatosplenic T-cell lymphoma
• * Angioimmunoblastic T-cell lymphoma
• * Subcutaneous panniculitis-like T-cell lymphoma
• * Chronic lymphocytic leukemia (CLL)
• Patients with NHL or CLL must meet the following criteria:
• * Ineligible for, or refused potentially curative stem cell transplantation
• * Transformed lymphoma/Richter's transformation, defined as the transformation of low-grade lymphoma, including follicular lymphoma, CLL, or small lymphocytic lymphoma to high-grade lymphoma (i.e., diffuse large cell lymphoma) allowed at time of transformation
• * Evidence of ≥ 50% bone marrow involvement at the time of enrollment OR tumor tissue accessible for biopsy (for patients enrolled after the maximum tolerated dose \[MTD\] is determined)
• * Absolute neutrophil count ≥ 1,000/mm\^3
• * Platelet count ≥ 100,000/mm\^3
• Relapsed or refractory disease
• Willing to undergo serial bone marrow biopsy (for patients enrolled after the MTD is determined)
• No untreated or active CNS leukemia or lymphoma
• Performance status - ECOG 0-2
• At least 12 weeks
• Bilirubin ≤ 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal
• Creatinine ≤ 2.0 mg/dL
• No uncontrolled cardiac disease
• No New York Heart Association class III-IV symptomatic congestive heart failure
• No unstable angina pectoris
• No serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation \> 3 beats in a row) within the past 6 months
• No other uncontrolled cardiac arrhythmia or requiring antiarrhythmic drugs
• No myocardial infarction within the past year
• No active ischemic heart disease within the past year
• No congenital long QT syndrome
• No left bundle branch block
• QTc ≥ 450 msec (for men) or 470 (for women) on ECG/EKG
• No history of LVEF \< 50% by MUGA or echocardiogram
• Resting ejection fraction ≥ 50% by MUGA or echocardiogram
• No prior history of cardiac toxicity after receiving anthracycline therapy (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, or mitoxantrone hydrochloride)
• No uncontrolled pulmonary disease
• No symptomatic pulmonary disease requiring oxygen or medications
• DLCO (i.e., oxygen diffusion capacity) ≥ 80% on pulmonary function testing
• Resting and exercise oxygen saturation ≥ 90% by pulse oximetry
• No ongoing pulmonary symptoms ≥ grade 2 including any of the following:
• * Dyspnea on or off exertion
• * Paroxysmal nocturnal dyspnea
• * Significant pulmonary disease including chronic obstructive or restrictive pulmonary disease
• * No prior history of pulmonary toxicity after bleomycin or carmustine
• No Medicare requirement for home oxygen (e.g., Resting O\_2 saturation ≥ 90% or desaturation to ≥ 90% with exertion)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No preexisting sensory or motor peripheral neuropathy ≥ grade 2
• No history of allergic reaction to eggs
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• Prior stem cell transplantation for relapsed or refractory disease allowed
• At least 2 weeks since prior immunotherapy and recovered
• At least 2 weeks since prior chemotherapy (excluding hydroxyurea) and recovered
• No other concurrent chemotherapy
• No concurrent routine corticosteroids except for treatment of other medical problems (e.g., pulmonary, rheumatologic, or adrenal disorders)
• At least 2 weeks since prior radiotherapy and recovered
• No prior radiotherapy that potentially included the heart in the field (e.g., mantle)
• No prior history of chest radiation
• No concurrent palliative radiotherapy
• At least 2 weeks since prior investigational therapy
• Prior bortezomib allowed
• No other concurrent commercial or investigational agents or therapies for the malignancy